missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Gibco™ Human IFN-alpha 2 (alpha2a) Recombinant Protein, PeproTech®
Click to view available options
Quantité:
1 mg
100 μg
20 μg
250 μg
500 μg
Conditionnement:
100µg
1mg
20µg
250µg
500µg
Description
Recombinant Human IFN-alpha (2a) is a 19.3 kDa protein containing 166 amino acid residues. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
IFN alpha (Interferon alpha) is a Type I interferon belonging to a family of structurally related, species-specific proteins exclusive to vertebrates. The interaction of IFN-alpha with its receptor component result in the activation of a number of signaling pathways which are mainly involved in innate immune response against viral infection. In humans, the gene for IFN alpha is located on on chromosome 9. The type I interferons consist of 14 different alpha isoforms (subtypes with slightly different specificities), and single beta, omega, epsilon and kappa isoforms. Homologous molecules are found in many species, including rats and mice (and most mammals), and have been identified in birds, reptiles and fish species. IFN alpha is produced primarily by plasmacytoid dendritic cells, is a potent component of the anti-viral innate immune response and modulates adaptive immunity. Diseases associated with the dysfunction of IFN alpha include Hepatitis C and Hepatitis.
Spécification
Spécification
| Numéro d’adhésion | P01563 |
| À utiliser avec (application) | Functional Assay |
| Format | Lyophilized |
| Formule | protein with no preservative |
| Identification génétique (Entrez) | 3440 |
| Poids moléculaire | 19.3 kDa |
| Nom | Human IFN-alpha 2 (alpha2a) |
| Méthode de purification | HPLC, SDS-PAGE |
| Quantité | 1 mg |
| État réglementaire | RUO |
| Afficher plus |
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu